Overview An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes Status: Completed Trial end date: 2010-09-01 Target enrollment: Participant gender: Summary The purpose of this study is to demonstrate the efficacy, safety, and tolerability of TA-7284 compared with placebo in patients with type 2 diabetes. Phase: Phase 2 Details Lead Sponsor: Mitsubishi Tanabe Pharma Corporation